Fig. 5.

IT-101 (10 mg/kg, i.v., qwk × 3) had superior antilymphoma activity as compared to IT-101 (5 mg/kg, i.v., qwk × 3) and CPT-11 in disseminated human anaplastic large T-cell xenografts. NOD.scid/NCr mice were intravenously injected with ffLuc⁺ Karpas 299 cells to establish disseminated human anaplastic large T-cell xenografts and treated with the indicated cytotoxic agent beginning eight days later. Treatment arm included untreated control (■), CPT-11 (100 mg/kg, i.p., qwk × 3) (◇), IT-101 (5 mg/kg, i.v., qwk × 3) (○), and IT-101 (10 mg/kg, i.v., qwk × 3) (x). The tumor burden was monitored longitudinally by quantification of tumor-derived ffLuc-activity. (A) Total photon flux normalized for exposure time and surface area and expressed in units of photons/second/cm²/steradian (p/s/cm²/sr) for individual mice was graphed over time and serial pseudocolor images representing light intensity from Karpas 299⁺ ffLuc in selected mice were shown. (B) Kaplan-Meier survival curves for each treatment group. The log-rank test was used to compare the percent animal survival between treatment groups. IT-101 (10 mg/kg, i.v., qwk × 3) treated animals had significantly longer survival as compared to those treated with IT-101 (5 mg/kg, i.v., qwk × 3) and those treated with CPT-11 (P = 0.0009, P = 0.0049, respectively). Points indicate mean survival.